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   Abstract 
Synthesis of Cyclic mitochondria penetrating peptides (MPPs) coordinated with Ir(III) complex and 
pH-responsive charge conversion MPPs , 2016, Jae-Hyeong Park, Graduate Program of Chemistry, 
Ulsan National Institute of Science and Technology(UNIST). 
 
Selectively targeting and accumulating the photosensitizers (PS) inside the cancer cells have 
considerable interest. Herein, we report simple, biocompatible and robust technique for the 
conjugation of iridium to the MPPs complexes to target the mitochondria of cancer cells. While 
considering the organelle specific targeting, the mitochondria have received vital merits, upon their 
ability to induce apoptosis and they become an ideal target for several PDT agents. Cyclic [HK(Fxr)nH] 
and corresponding linear peptide [K(Fxr)nHH] were conjugated with Ir(III) complexes[Red and 
Green]. Ir(III) complexes and histidine (His) which has positively charged amino acid can easily bind 
through coordination between imidazole side chain of histidine (His) and metal which is highly 
efficient and easily synthesized through cyclization procedure. As a result, this effectively develop 
designed strategy for PDT agent based on Ir(III) complexes, which specifically targeted the 
mitochondria. Moreover, this cyclic modified complexes showed an improved PDT effect compared 
to linear one, meaning of a potent mitochondria-targeted PDT agents in antitumor therapy. Although 
both forms possess abundant charge, cyclic structure with rigidity is ability to result in an ideal 
interface for interaction with membrane constituent more than flexible structure. 
Stimuli responsive degradation of chemical bonds are useful tools for the development of ‘smart 
materials’ which have remarkable applications in stimuli responsive drug delivery system. The pH is 
commonly applied to the cancer specific drug delivery system, because the pH near the tumor or in 
the tumor extracellular environment significantly acidic as pH 6-6.5 while the normal physiological 
pH is around 7.4. In this study, we designed and developed mitochondria targeting short peptide with 
charge conversion depending on pH values. The peptide sequences consists of FxrFxKK, possess 
positive charge and lipophilic character for targeting mitochondria. We conjugated drug (PU-10-
COOH) as an inhibitor of HSP90 and maleic derivatives which are play a role of hydrolyzed in MPPs. 
Once maleic conjugated MPP extravagates into cell membrane through highly permeability, amide 
bonds within conjugate occur hydrolysis, reproducing intrinsic properties of MPP in the acidic tumor 
extracellular fluids (pH < 7) for cellular uptake and mitochondria targeting. Moreover, this platforms 
shows anticancer effect at 20 μM concentration. Therefore, we hope that this model conjugated 
peptides have a potent of cancer therapy agent 
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Chapter 1. Introduction 
  
1.1 Mitochondria penetrating peptides (MPPs) 
 
Mitochondria is a candidate of interesting targets for organelle-specific cancer chemotherapy, since 
mitochondria have merits of important role, which possess not only energy production but 
programmed cell death [1,2]. However, a significant challenge to access of mitochondrial transporters 
within this organelle can be difficult, because the inner membrane have the impervious structure of 
the hydrophobic properties [3]. To solve this issue, mitochondria penetrating peptides (MPPs) have 
been develop. This MPPs are some kinds of cell-permeable peptides that are able to enter 
mitochondria membrane [4]. The sequences of the MPPs exhibits positive charge and lipophilic 
character for translocation both the plasma membrane and mitochondrial membranes. Among the 
amino acids, lysine (K) and arginine (R) provide positive charge, and phenylalanine (F) and 
cyclohexylalanine (FX) residues have a lipophilicity. Delocalized lipophilic cationic units are known 
to predominantly accumulate in mitochondria in response to negatively charged intra-trans membrane 
potentials [4]. Moreover, arginine-based peptides such as Tat, which known as CPPs, have high levels 
of cellular uptake [5]. By altering aromatic (lipophilicity) and cationic residues, MPPs shows 
successful delivery for mitochondrial location. The sequence of MPPs are presented in Table 1.1. 
Table 1. 1 Evaluation of Mitochondrial Localization for Synthetic Peptide Conjugates [27]. 
(*Reprinted with permission) 
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1.2 Histidine-Ir(III) complex coordination method 
 
Wang et al reported that through the combined coordination of Ir(III) complex, peptide luminogenic 
cyclization method developed an easy-to-use and versatile method [6]. Some cyclometalated 
Iridium(III) solvent complex can be ability to use a selective luminogenic probe [7]. Moreover, the 
imidazole unit of histidine side chains contained the pair of free electrons can be able to attach to 
metal ions. When in a peptide bond, an –NH2 group in adjacent neighborhood of a histidine residue 
show negiligible influence on coordination of histidine residues with Ir(III) complex (Figure 1.1.a,b). 
But, N-terminally placed histidine can bind to Ir(III) complex. 
 
Figure 1. 1 Kinetics of the luminogenic reaction with Ir(III) complex and peptides [6]. (*Reprinted 
with permission) 
 ３ 
 
 
Also, peptide with two histidine placed each terminus can be used to coordination with Ir(III) 
complex [8]. This peptide can make cyclic formation with the different ring sizes by placing other 
sequences of amino acid between two histidine. By utilizing these located sequences of amino acid, 
cyclic peptide with Ir(III) complex have ability to accumulate organelle with targeting peptide. 
Because peptide can be tethered to anticancer drug, these cyclic peptides are more beneficial in cancer. 
So, the combination of structural modification and phosphorescent labeling properties may provide 
multifunctional effect for biomedicine applications.  
 
 
Figure 1. 2 Enhanced and selective cytotoxicity of Ir−HRGDH−KLA [8]. (*Reprinted with 
permission). 
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1.3 Cyclic form Verses Linear peptide for cellular uptake 
  
Cyclic peptides generally impermeable to the cell membrane. However, the combination of cell-
penetrating peptide can be lead to overcome their applications against intracellular targets with 
resulted in cell-permeable [9]. Moreover, cyclic peptides exhibit a great potential as therapeutic agents, 
because the ability of a general intracellular delivery are more effective than linear form peptides [10]. 
As shown Figure 1.3.a, cyclic peptide (DOX-[W(RW)4]) shows more higher cellular uptake than 
linear peptide(DOX-[RW]5) [26]. Moreover, cyclic Tat entered living cells more effectively than linear 
Tat [11]. Although both forms possess abundant charge, cyclic structure with rigidity is ability to result 
in an ideal interface for interaction with membrane constituent more than flexible structure [11]. So, the 
cyclic form can be not only able to translocate into living cells compared to linear form but enhanced 
significantly transduction kinetics. 
 
Figure 1. 3 FACS analysis of cellular uptake assays of cyclic peptide in SK-OV-3 cells [26]. 
(*Reprinted with permission) 
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1.4 Cyclometalated Ir(III) complexes 
 
Recently, cyclometalated iridium(III) complexes are widely developed as biosensing agents, which 
exhibit superior photophysical properties, e.g, high quantum yield, large stokes shifts, long lived 
phosphorescence, good phtostability, cell permeability [12-15]. Ir(III) complexes based on PDT agents 
also exhibit strong anticancer potential by controlling their energy levels to achieve marked ROS 
generation [16-17]. When this Ir(III) complex exposed to a specific wavelength of light, the excited 
complex move its energy to the ambient molecular oxygen (3O2) to generate 1O2 and other toxic 
reactive oxygen species (ROS), which can lead to the cell death [26](Figure 1.4). In addition, 
photophysical and biological properties of Ir(III) complexes can be changed due to the easy 
modification of the ligands. 
 
Figure 1. 4 Proposed mechanism for the photophysical processes of Irbtp–RhB [25]. (*Reprinted with 
permission) 
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1.5 Charge conversion delivery 
 
pH-responsive degradation of chemical bonds is useful tool for stimuli-responsive drug-delivery 
systems [18]. Various pH-sensitive chemical bonds such as acetal, orthoester, imine, and 
phosphoramidate moieties have ability to degrade at mild pH changes [19-22]. Recently, Maleic acid 
amide derivatives are known as candidates of pH-sensitive moiety. Most of them can be able to 
degrade at mild acidic pH conditions since these moieties can be attributed to the internal reaction of 
amide carbonyl group by the carboxylate [23-24], inducing change of the chemical structure of maleic 
acid amide. Also, carboxylate groups within maleic acid amide derivatives exhibit negative charges at 
basic conditions. But, after degradation at acidic conditions, maleic acid amide bond turn to their 
original form, maleic acid groups with exposing positively charged amine groups. This negative-to-
positive charge conversion in maleic acid amide derivatives have been modified in order to increase 
the negative charge density of lipids and polymers for the effective pH-triggered drug delivery.  
 
 
Figure 1. 5 Schematic representation showing the preparation of the charge-conversional PIC 
micelles [28]. (*Reprinted with permission) 
 ７ 
 
1.6 Thesis summary 
 
Mitochondria represents a candidate of interesting targets for organelle-specific cancer 
chemotherapy, since mitochondria have merits of important role, which possess not only energy 
production but programmed cell death. However, a significant challenge to access of mitochondrial 
transporters within this organelle can be difficult, because the inner membrane have the impervious 
structure of the hydrophobic properties. To solve this issue, mitochondria penetrating peptides (MPPs) 
have been develop. This MPPs are cell-permeable peptides that are able to enter mitochondria 
membrane. Moreover, they can accumulate in the mitochondria because of positive charge and 
liphophlicity within the side chain of peptide. But, these peptide also have some limitations. Since 
MPPs possess mitochondria targeting ability by charge driven, they can go to mitochondria in normal 
cell. Although mitochondria in tumor cell is more negative charge than normal cell, charge driven 
ability of MPPs may affect inhibition of anti-cancer ability. And MPPs can’t deliver cargo with high 
M.W. To overcome this limitation, highly efficient cellular uptake and selectivity ability are the most 
needed.  
 
In Chapter 2, the synthesis and characterization of newly MPPs coordinated with Ir(III) complex are 
discussed. Ir(III) coordinated peptides depending on different sequence of mitochondria penetrating 
peptide and conformation are also described. Designed compound were characterized for PDT. 
Chapter 3 summarizes the synthesis of charge conversion MPPs and Checks the anti-cancer ability. 
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2. Cyclic Mitochondria-penetrating peptides (MPPs) with Ir(III) complex 
for mitochondria-targeted anticancer theranostics and photodynamic 
therapy 
 
2.1 Abstract  
 
Selectively targeting and accumulating the PS inside the cancer cells have considerable interest and 
non-toxic. Herein, we report simple, biocompatible and robust technique for the conjugation of 
iridium to the MPPs complexes to target the mitochondria of cancer cells. Cyclic [HK(Fxr)nH] and 
corresponding linear peptide [K(Fxr)nHH] were conjugated with Ir(III) complexes[Red and Green]. 
Ir(III) complexes and histidine (His) which has positively charged amino acid can easily bind through 
coordination between imidazole side chain of histidine (His) and metal which is highly efficient and 
easily synthesized through cyclization procedure. As a result, this effectively develop designed 
strategy for PDT agent based on Ir(III) complexes, which specifically targeted the mitochondria. 
Moreover, this cyclic modified complex exhibited an improved PDT effect compared to linear one, 
meaning of a higher potent mitochondria-targeted PDT agents for cancer therapy. 
 
2.2 Introduction  
 
Increasing modalities by non-invasive techniques are promising strategy for cancer treatment [1]. 
Recently, these noninvasive treatments have received considerable due to their treatment efficacy and 
widely used for several therapies including cancer [2]. PDT has been successfully used to treat 
epidermal cancer by illuminating the photosensitizers (PS) to generate reactive oxygen species (ROS) 
upon the activation of light [3]. Several photosensitizing agents such as porphyrin, chlorin and 
zanthenese are conventionally applied and developed for clinics [4]. For instance, photofrins which are 
porphyrin derivatives clinically generate ROS, to kill the cancer cells [5]. However, the limitations of 
the photofrins include inefficient light penetration in deep tissues, low molar absorption coefficient 
(1,170 M-1 Cm-1)) which needs both high concentrations of sensitizer and long light time, and non-
selectivity for tumor [6-8]. Recently, Iridium (III) complexes in PDT have received significant attention 
due to its stability and efficacy [9-10]. Upon specific wavelength of light, the excited PS relocate its 
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energy to the ambient molecular oxygen (3O2) to generate 1O2 and other toxic reactive oxygen species 
(ROS), which can lead to the cell death. Ir(III) complexes have received significantly recognition as 
bio-imaging agent because of their rich photophysical properties involving large stokes shifts, high 
quantum yield, long-lived phosphorescence, outstanding color tuning capability and good resistance 
to photo-bleaching [11-15].Moreover, the photophysical and biological properties of Ir(III) complexes 
can be readily tuned due to the easy modification of the ligands. Poor solubility and non-selective 
accumulations in reticuloendothelial systems (RES) may lead to failure of this design and unwanted 
toxicity. Selectively targeting and accumulating the PS inside the cancer cells have considerable 
interest and non-toxic.  
 
Peptides received wide interest in targeting the cancer cells. Peptides are known to be biocompatible 
and highly soluble in several organic solvents and aqueous suspensions. Modifying the amino acid 
sequence of these peptides, such as cell penetrating peptides can selectively accumulate inside the 
cancer cells. Cell penetrating peptides (CPPs) such as Tat have the ability to cross the cell membrane 
[16-17]. Especially, mitochondria penetrating peptides (MPPs) are important CPP, can enter both the 
plasma and mitochondrial membranes [18]. MPPs are extensively used for targeting cancer cells 
because they impart positive charge and lipophilic character in the side chains of amino acid, which 
increase its affinity towards mitochondria [18-19]. Interestingly, cyclic peptides have significant 
advantages such as enhanced cellular uptake due to cyclic structure with rigidity is ability to result in 
an ideal interface for interaction with membrane constituent more than flexible structure. Recently, 
cyclic arginine-rich CPPs showed amplified cellular uptake compared to their linear CPPs with 
flexibility. Cyclized CPPs are not only able to translocate into living cells with comparable to linear 
form but exhibit enhanced transduction [20]. Specific organelle targeting in cancer treatment have 
robust efficacy. Specific organelle localization of the PS improves the treatment efficacy in cancer and 
investigated in detail [21]. Target specificity of PS can be achieved by controlling the functional groups 
of the agents and peptides have major role in cancer targeting [22]. PDT agents can be conjugated to 
peptides under mild reaction condition and can be delivered at the target location. While considering 
the organelle specific targeting, the mitochondria have received vital merits, upon their ability to 
induce apoptosis and they become an ideal target for several PDT agents. 
 
Herein, we report simple, biocompatible and robust technique for the conjugation of iridium to the 
MPPs complexes to target the mitochondria of cancer cells. Cyclic [HK(Fxr)n-H] and corresponding 
linear peptide [K(Fxr)n-HH] were conjugated with Ir(III) complexes[Red and Green]. Ir(III) 
complexes and histidine (His) which has positively charged amino acid can easily bind through 
coordination between imidazole side chain of histidine (His) and metal which is highly efficient and 
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easily synthesized through cyclization procedure [23-24]. As a result, this effectively develop designed 
strategy for PDT agent based on Ir(III) complexes, which specifically targeted the mitochondria 
(Scheme 2. 1). Moreover, this cyclic modified complex exhibited an improved PDT effect compared 
to linear one, meaning of a potent mitochondria-targeted PDT agents for antitumor therapy.  
 
 
Scheme 2. 1 Schematic representation of overall process for PDT by using Ir(III) complex 
modifications with MPPs. 
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2.3 Experimental  
 
Materials and Methods  
 
All reagents and chemicals were purchased from commercial sources and used as received. Amino 
acids (Fmoc-Lys(Boc)-OH, Fmoc-His(Trt)-OH, Fmoc-d-arg(Boc)-OH, Fmoc-Cha-OH) and rink 
amide MBHA resin were obtained from BeadTech (Korea) and ApexBio (USA), Coupling reagent(O-
benzotriazole-N,N,N’,N’-tetramethyluronium hexafluorophosphate, HBTU) was obtained from 
ApexBio (USA). N,N-diisopropylethylamine(DIPEA) and trifluoroacetic acid (TFA) were purchased 
from TCI (Japan). Triisopropylsilane and piperidine were obtained from Sigma-Aldrich (USA). N,N-
dimethylformamide(DMF), Methanol and Acetonitrile (ACN) HPLC grade was purchased from 
DAEJUNG(South Korea) . Iridium(III) chloride hydrate (Strem Chemicals, MA, USA), 2-
phenylpyridine (Sigma Aldrich, MO, USA), 2-phenylquinoline (Sigma Aldrich, MO, USA), silver 
trifluoromethanesulfonate (Alfa Aesar, MA, USA) were used as materials for synthesis and analysis. 
All of solvents were prepared from SAMCHUN Chemicals, Korea. Analyses for production of 
reactive oxygen species (e.g., singlet oxygen (1O2) and superoxide radical (O2•-)) utilized 9,10-
anthracenediyl-bis(methylene)dimalonic acid (ABDA) and dihydrorhodamine 123 (DHR123) that 
were purchased from Sigma Aldrich.   
 
 
Characterization 
 
HK(Fxr)nH peptides, K(Fxr)nHH peptides and Ir(III) complex modified peptides were characterized 
using MALDI-TOF. Analyses for two synthesized Ir(III) complexes were previously reported [25]. 
Therefore, utilized two Ir(III) complexes (RED and GREEN) were checked by 1H NMR spectroscopy 
analysis (UNIST Central Research Facilities, Agilent 400 MR-DD2 NMR spectroscopy, Republic of 
Korea). Photo-physical studies for each Ir(III) complexes that finish to bind with six peptides (either 
cyclic or linear) were proceeded by an UV-2600 UV-visible spectrophotometer (Shimadzu, MD, 
USA), a Varian Cary Eclipse fluorescence spectrophotometer (Agilent, CA, USA), and PicoHarp 300 
time-correlated single photon counting (TCSPC) (PicoQuant, Berlin, Germany). The irradiation 
source for photo-activation of Ir(III) complexes binding with a peptide made use of IQE-200 solar 
simulator (Newport, CA, USA). 
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Synthesis of peptide (HK(Fxr)nH, K(Fxr)nHH) 
 
Solid phase peptide synthesis (SPPS) was performed by an automated peptide synthesizer. 200 mg of 
resin was swollen in DMF solution. After 30 min, operate machine to synthesize peptide. Peptide 
scale is 0.1mM. Amino acid solution was prepared by dissolving Fmoc-His(Trt)-OH 0.372 g in 6ml 
DMF, Fmoc-Lys(Boc)-OH 0.141 g in 3 mL DMF, Fmoc-d-arg(Boc)-OH 0.195 g(0.195*n) in 3 
mL(3*n) DMF,. And Fmoc-Cha-OH 0.117 g(0.117*n) in 3 mL (3*n) DMF. Fmoc deprotection of the 
Fmoc- amino acids was performed by adding 20% piperidine solution in DMF. HBTU and DIPEA act 
as coupling reagent and base. After finishing final deprotection of Fmoc protecting group, make 
cleavage cocktail (TFA: triisopropylsilane: Water = 4.75 mL: 0.25 mL: 0.25 mL). Add cleavage 
cocktail into resin with stirring for 4 hours at room temperature. Then, precipitate with cold diethyl 
ether. The peptide is purified through High Performance Liquid Chromatography (HPLC) using 
water/Acetonitrile. 
 
 
 
Scheme 2. 2 Molecular structure of newly synthesized mitochondria targeting peptides. 
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Figure 2. 1 MALDI-MS analysis of HKFxr2H peptide. (M.W: 1,038 g/mol) 
 
 
 
Figure 2. 2 MALDI-MS analysis of HKFxr3H peptide. (M.W: 1,347 g/mol) 
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Figure 2. 3 MALDI-MS analysis of HKFxr4H peptide. (M.W: 1,657 g/mol) 
 
 
 
Figure 2. 4 MALDI-MS analysis of KFxr2HH peptide. (M.W: 1,038 g/mol) 
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Figure 2. 5 MALDI-MS analysis of KFxr3HH peptide. (M.W: 1,347 g/mol) 
 
 
 
Figure 2. 6 MALDI-MS analysis of KFxr4HH peptide. (M.W: 1,657 g/mol) 
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Procedure for Ir(III) complexes synthesis (GREEN and RED).  
 
Procedure for synthesizing [(ppy)2Ir(OH2)2]+OTf– (GREEN) and [(2pq)2Ir(OH2)2]+OTf– (RED) is 
only two step process. Firstly, Iridium dimers that incorporates each ligand (2-phenylpyridine (ppy) 
and 2-phenylquinoline (2pq)) were prepared as previously reported method [26].Without further 
purification for iridium(III) dimers, next step was subsequently proceeded. A solution of dimer (1 
equiv.) and silver trifluoromethanesulfonate (AgOTf) (2.2 equiv.) dissolved in EtOH:H2O = 9:1 (v/v) 
solvent mixture refluxed for 24 hours. Resident solvent was removed in vacuo after cooling down 
reaction pot. Crude product extracted with CH2Cl2. Product was separated from other crude material, 
utilizing solubility difference. After product separation as much as possible, recrystallization of 
product with chloroform and pentane. After purification, yellow and orange color powders (GREEN 
and RED, respectively) were obtained.  
 
[(ppy)2Ir(OH2)2]+OTf– (GREEN) 1H NMR (400 MHz, D2O): δ (ppm) = 8.770 (s, 1H), 7.928 (d, J = 
29.9 Hz, 2H), 7.580 (m, 1H), 7.361 (dd, J = 12.0, 6.2 Hz, 1H), 6.788 (dd, J = 11.5, 7.4 Hz, 1H), 6.619 
(dd, J = 10.8, 7.0 Hz, 1H), 6.084 (m, 1H). 
 
[(2pq)2Ir(OH2)2]+OTf– (RED) 1H NMR (400 MHz, d6-CD3CN): δ (ppm) = 8.834 (d, J = 8.9 Hz, 1H), 
8.585 (d, J = 8.7 Hz, 1H), 8.273 (d, J = 8.8 Hz, 1H), 8.120 (d, J = 8.1 Hz, 1H), 7.905 (ddd, J = 8.7, 7.0, 
1.5 Hz, 1H), 7.864 (d, J = 7.4 Hz, 1H), 7.770 (t, J = 7.5 Hz, 1H), 6.993 (t, J = 7.5 Hz, 1H), 6.704 (dd, J 
= 11.8, 4.4 Hz, 1H), 6.133 (d, J = 7.4 Hz, 1H). 
 
 
Scheme 2. 3 Synthetic scheme of H2O coordinated Ir(III) complexes (GREEN and RED). (i) ligand 
(2 equiv.) and 2-methoxyethanol:H2O = 3:1 (v/v). (ii) Silver trifluoromethanesulfonate (AgOTf) (2.2 
equiv.) and CH2Cl2:MeOH = 1:1 (v/v). 
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Synthesis of Cyclic and linear form peptide with Ir(III) complexes  
 
Equal molar of peptides and Ir(III) complexes were incubated in water(>1% DMSO) for 2 h at room 
temperature for Ir-HH cyclization. In order to confirm synthesis, MALDI-MS were performed.  
 
[Green] 
 
 
 
Figure 2. 7 MALDI-MS analysis of HKFxr2H-Ir(Green). (M.W: 1,538 g/mol) 
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Figure 2. 8 MALDI-MS analysis of HKFxr3H-Ir(Green). (M.W: 1,848 g/mol) 
 
 
 
Figure 2. 9 MALDI-MS analysis of HKFxr4H-Ir(Green). (M.W: 2,157 g/mol) 
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Figure 2. 10 MALDI-MS analysis of KFxr2HH-Ir(Green). (M.W: 1,538 g/mol) 
 
 
 
Figure 2. 11 MALDI-MS analysis of KFxr3HH-Ir(Green). (M.W: 1,848g/mol) 
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Figure 2. 12 MALDI-MS analysis of KFxr4HH-Ir(Green). (M.W: 2,157 g/mol) 
 
 
 
  
1657.149
684.542
2157.204
581.955
894.452
0
250
500
750
1000
1250
1500
In
te
n s
. [a
.u
.]
600 800 1000 1200 1400 1600 1800 2000 2200
m/z
 ２４ 
 
Optical properties of peptide binding Ir(III) complexes.  
 
H2O:DMSO = 99:1 (v/v%) condition was used to prepare each 20 μM solutions (20 μM Ir(III) 
complex + 20 μM peptide). Solvent that is used to make solution is degassed with N2 gas bubbling. A 
1 cm × 1 cm cell (Hellma) and 1 cm × 0.2 cm cell (Hellma) for absorbance and emission analysis 
was used to measure steady-state optical properties, respectively.  
Each lifetime for peptide binding Ir(III) complexes was recorded with time-correlated single photon 
counting (TCSPC). Each sample was prepared as same with UV and PL solution ([Ir(III)] = 20 μM 
and [Peptide] = 20 μM). TCSPC consists of Ti:sapphire laser, Mira900 (Coherent Inc., CA, USA), 
monochromator, Acton series SP-2150i (Princeton Instruments, MA, USA), and TCSPC module, 
PicoHarp 300 (PicoQuant, Berlin, Germany) with a MCP-PMT, R3809U-59 (Hamamatsu Photonics, 
Japan). Excitation carried out with second harmonic generation (SHG = 420nm) with ~150 fs pulse 
width and 76 MHz repetition rate. The total instrument response function (IRF) for photon decay was 
less than 150 ps. The recorded results of phosphorescence lifetime decay for peptide binding Ir(III) 
complexes were fitted by FluoFit software. 
 
 
Figure 2. 13 Optical properties of peptide binding Ir(III) complex(Red). Upper images for cyclic 
peptide and bottom images for linear peptide. Absorbance: 451 nm, emission: 587 nm (DIW: DMSO= 
99:1) (This data taken by co-worker, Jung Seung Nam) 
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Figure 2. 14 Each lifetime for peptide binding Ir(III) complexes by recording with time-correlated 
single photon counting (TCSPC). 
 
 
Table 2. 1 Quantification data of Each lifetime for peptide binding Ir(III) complexes by recording 
with time-correlated single photon counting (TCSPC). (This data taken by co-worker, Jung Seung 
Nam) 
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Assays for singlet oxygen (1O2) and superoxide radical generation (O2•-).  
Singlet oxygen (1O2) generation was detected by chemical reaction between 1O2 and 9,10-
anthracenediyl-bis(methylene)dimalonic acid (ABDA). Standard ABDA absorbance was gradually 
declined, disconnecting conjugation of anthracene backbone of ABDA by 1O2 (Scheme 1). Ir(III) 
complexes and peptide solution were prepared as 10 μM using their stock solution of 1 mM in DMSO 
and 10 mM in distilled water. ABDA stock solution was prepared as 100mM in DMSO and it was 
added in Ir(III) complexes solution as 1000:1 volume ratio. These solutions for each peptide-binded 
Ir(III) complexes were irradiated with solar simulator for which light intensity was about 40% of 100 
mW cm-2 because ABDA could be decomposed by strong light source. The absorbance change of 
ABDA according to reaction with photo-activation induced 1O2 was recorded at every 1 minute. 
Analysis time for absorbance change was up to 5 minutes.  
 
 
Scheme 2. 4 Breakage of conjugation backbone of ABDA through 1O2 oxidation. 
 
To figure out relative amount of superoxide radical (O2•-) generation, furthermore, dihydrorhodamine 
123 (DHR 123) was utilized (Scheme 2). Ir(III) complexes (GREEN and RED) and peptides were 
prepared as 10 μM:10 μM with same process in ABDA assay (vide supra) and DHR 123 dissolved in 
DMSO to become 10 mM stock solution. DHR 123 stock was diluted in prepared Ir(III) complex + 
peptide solution as 1000:1 (v/v). Each sample was loaded in 48-well plate with 1 mL. Light source 
from solar simulator irradiated the plate that contains each solution with 100 mW cm-1 intensity 
during 5 minutes. Emission intensity change was recorded with fluorometer (λexc = 505 nm, λemis = 
529 nm).   
 
 
Scheme 2. 5 Formation of new conjugation of DHR 123 through oxidation by O2•- 
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Figure 2. 15 Absorbance change of ABDA for GREEN + peptide complexes. It is correlated with the 
amount of 1O2 generation by GREEN Ir(III) complex that incorporates either (a) cyclic or (b) linear 
peptide. (This data taken by co-worker, Jung Seung Nam) 
 
 
Figure 2. 16 Absorbance change of ABDA for RED + peptide complexes. It is correlated with the 
amount of 1O2 generation by RED Ir(III) complex that incorporates either (a) cyclic or (b) linear 
peptides. (This data taken by co-worker, Jung Seung Nam) 
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Cell culture and cell viability analysis. 
Human cancer cells originating from cervix (HeLa) and noncancerous fibroblast (HeK293T) cells 
were obtained and cultured in DMEM, L-15 or RPMI (Life Technologies) containing 10% fetal 
bovine serum (FBS; Life Technologies) and 1% penicillin/streptomycin (Life Technologies) at 37 ºC 
in a humidified atmosphere of 10% CO2. For cytotoxicity analysis, cells were cultured in sterile 96-
well Nunc (Thermo Fisher Scientific Inc.) microtiter plate at a seeding density of 5 x 103 cells/well 
and allowed to settle for 24 h under incubation at 37 °C and 5% CO2 in their respective growth 
medium (RPMI 1640 and DMEM etc.). In order to check cell viability, the cells were then treated 
with different concentrations of peptides (0.01, 0.1, 0.5, 1, 2, 3, 5, 10, 15 and 20 µM). After 8h of 
incubation, stipulated time of light irradiation (3 min, 5 min and 10 min) was performed, Cell viability 
was measured at 24 h using the alamar blue assay, with each data point measured in triplicate. 
Fluorescence measurements were made using the plate reader (Tecan Infinite Series, Germany) by 
setting the excitation wavelength at 565 nm and monitoring emission at 590 nm on the 96 well plates. 
 
Confocal microscope imaging 
 HELA cells were seeded in one well glass cover glass (Lab Tek II, Thermo Scientific) at a seeding 
density of 2 x 105 cells/well. In order to check cellular uptake of peptides, the cells were then treated 
with different concentrations of peptides at 5 µM for 1h. The cellular uptake was monitored 
periodically using Olympus FV1000 microscope connected to CO2 incubator. 
 
Flow-cytometry analysis.  
HeLa cells were seeded on a 25 mL T-flask (Thermo Scientific) in DMEM (Life Technologies) 
supplemented with 10% FBS and 1% penicillin/streptomycin at 37 °C and 5% CO2. Then the cells 
were incubated with 10 μM of peptides for a period of 8h and irradiated in light for 5 min. Then the 
cells were harvested and washed in cold phosphate-buffered saline (PBS). By following the 
manufacturer’s protocol (Life Technologies, V13241), were were incubated with 5 µL Alexa Fluor® 
488 annexin V and 1 µL 100 µg/mL PI working solution in 100 µL of annexin-binding buffer solution 
for 15 min at room temperature. After the incubation period, 400 µL 1X annexin-binding buffer were 
added, mixed gently and keep the samples on ice. Immediately, analyze the stained cells by flow 
cytometry (FACS caliber, BD Bioscience), measuring the fluorescence emission at 530 nm (e.g., FL1) 
and >575 nm (e.g., FL3).   
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 2.4 Results and Discussion  
 
 
1) Characterization of Ir-HH cyclization of peptides of different conformation. 
 
 
Figure 2. 17 Analyses for peptide binding with Ir(III) aquo complexes. (a) Molecular structure of 
Ir(III) aquo complexes and newly synthesized mitochondria targeting peptides. Hill’s binding assay 
and kinetic observation of phosphorescence for RED complex with (b) cyclic or (c) linear peptides. (d) 
Specific values of EC50 and Kd . (This data taken by co-worker, Jung Seung Nam) 
 
 
We first synthesized a series of model cyclic and linear peptides with increasing number of d-
arginine (r) and cyclohexyl alanine (Fx) placed between lysine (K) and histidine (H)( cyclic: 
HK(Fxr)nH, linear: HK(Fxr)nH, n = 1,2,3)(Figure 2. 23a). These peptides all produced red 
phosphorescence after 2h of incubation with Ir(III) complex.  
The binding affinity between Ir(III) complex and model peptides was determined by Hill’s binding 
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assay. In the assay, reaction mixture were prepared with different peptide ratios when concentrations 
of Ir were fixed at 100 μM. As shown Figure 2. 17b-c, while cyclic peptides have a binding affinity 
enhancement depending on length of pendant group, linear peptides show no change of binding 
affinity because of fixed binding motion.  
 
Moreover, we checked the kinetic observation of phosphorescence for red with time dependent 
(Figure 2. 17b-c). According to time duration, phosphorescence from peptide binding Ir(III) 
complexes was saturated. From this kinetic analysis, we can calculate koff and kon value from 
Michaelis-Menten equation based fitting process. This phosphorescence reaction allows a simple 
estimation of Ir(III)-peptide binding equilibriums (EC50). In the series, cyclic HKFxr3H exhibited 
strong binding to Ir(III) than all other peptides(Figure 2. 17d). 
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2) Primary subcellular localization of cyclic MPPs conjugates in living cells. 
 
 
 
Figure 2. 18 Live-cell confocal microscope images of HeLA cells after incubation with Red-Ir 
complex (Em: 583 nm) conjugated peptides (linear & cyclic) for 1h. Co-localization analysis with 
mitotracker green FM (green pallet; Em: 454 nm). 2D histogram images to analyze the 
extent/significance of location between green pallet and red pallet. R – Pearson correlation value. 
Cyclic peptide-Ir(red) (upper) and linear peptide-Ir(red) (bottom). Concentration: 10 𝜇M. 
 
To determine the subcellular localization of Ir-peptides, we imaged Ir-peptides localized region in 
HeLa cell line. with two iridium (III) complexes, respectively. Totally 12 samples are prepared with 
different conformation (green emitted six samples, red emitted six samples). Cyclic peptides have 
been already study compare with linear peptides and cyclic peptide with CPPs have high level of 
cellular uptake more than linear one. Based on this knowledge, we hypothesized that our cyclic form 
compound also possess more efficient in cellular uptake than linear form one. We check the 
localization in mitochondria compared with cyclic and linear form model compounds through the 
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confocal microscopy. We treated all samples (10 μM) in the Live HeLA cells with incubation 1h. As 
shown in Figure 2. 18, we can observe that cyclic MPPs conjugates show higher cellular uptake than 
linear one. Green Ir-peptides also shows similar results (Figure 2. 19). This data suggest that cyclic 
MPPs-Ir (III) can be used as improving the cellular delivery.  
 
 
Figure 2. 19 Live-cell confocal microscope images of HeLA cells after incubation with Red-Ir 
complex (Em: 583 nm) conjugated peptides (linear & cyclic) for 1h. Cyclic peptide-Ir(RED): (a) 
HKFxr2H-Ir (b) HKFxr3H-Ir (c) HKFxr4H-Ir, Linear peptide-Ir(RED): (d) KFxr2HH-Ir (e) 
KFxr3HH-Ir (f) KFxr4HH-Ir. Co-localization analysis with mito tracker deep red FM. Green color 
(Em: 454 nm) and Red –mitotracker (Em: 555 nm). 2D histogram images to analyze the 
extent/significance of location between green pallet and red pallet. R – Pearson correlation value. 
Concentration : 10 𝜇M. 
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Figure 2. 20 FACS analysis to check the cellular uptake of a) Green Ir and b) Red Ir complex 
conjugated peptides in HeLA cells after 1h incubation. Concentration: 10 μM. 
 
 
To check the cellular uptake of Green and Red Ir(II)complex conjugated peptide, we analyzed FACS 
data in HeLA cells after 1h incubation  (Figure 2. 20). We can observe the cyclic peptide are more 
enter the cell than linear one with both iridium complex conjugates.  
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Figure 2. 21 a,b) Flow cytometry analysis to measure the energy independent uptake mechanism in 
HeLA for cyclic(a) and linear(b) Red Ir peptides after 1h incubation at 37C and 4C. C) Live cell 
confocal microscope images of HeLA cells after 1h incubation with Red Ir complex conjugated 
linear(bottom) and cyclic peptides(upper) (Em: 583 nm). Scale bar in 10 μM and 5 μM. 
 
Moreover, we check whether the mechanism of cellular uptake is energy dependent or independent. 
As a results, these peptides are energy independent process (Figure 2. 21). 
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3) Ir(III)-MPPs as Photodynamic therapy (PDT) Agents.  
 
 
Figure 2. 22 Photodynamic therapy experiment for red iridium complex conjugated peptide. a-b) 
Estimation of two reactive oxygen species (superoxide radical and 1O2) generation with 
dihydrorhodamine 123 (DHR 123) or 9, 10-anthracenediyl-bis(methylene)dimalonic acid (ABDA) 
before/after peptide binding. DHR 123 (left, bar graph) and ABDA assay (right, decay line) with RED. 
c-d) Cell viability analysis for Ir complex conjugated peptides upon the irradiation (right) and without 
irradiation(left). Concentration: 10 μM. 100 mW cm−2 light; irradiation time = 300 s. (ABDA, DHR 
data taken by co-worker, Jung Seung Nam) 
 
The ROS generation ability of Ir(III) complexes according to their energy levels was identified by 
two different analyses: triplet state quenching by O2, 9,10-anthracenediylbis(methylene) malonic acid 
(ABDA) assay for 1O2 generation, and dihydrorhodamine (DHR) 123 assay for superoxide radical 
(O2•−) generation. Triplet state quenching of Ir(III) complexes by O2 bubbling relates to the amount of 
formed ROS, because it strongly depends on 1O2 generation and charge transfer interactions from 
Ir(III) complexes to O2, resulting in oxygen radical formation. The quenching rate order is HkFxr3H > 
HkFxr4H > HkFxr2H, suggesting that HkFxr3H is the best photoactivatable ROS generator for PDT in 
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our system (Figure 2. 22b). In contrast, green iridium complex conjugates produce the little amount of 
singlet oxygen (Figure 2. 23b). In the DHR 123 assay, the relative rates for O2•− production are in 
order of HkFxr3H > HkFxr4H > kFxr3HH > HkFxr2H = kFxr2HH= kFxr4HH> Ir(III) complex(red). 
Basically, DHR 123 activation ability was shown better in RED complexes than in Green complexes. 
(Figure 2. 22a, 23a).  
 
 Next, we conduct cell-viability with and without irradiation. While we can see the high level of 
cytotoxicity (20~60%) under irradiation (time: 300s), in the dark site, we don’t observe the 
cytotoxicity (Fig. 2. 22 c-d). This cyclic modified complex exhibited an improved PDT effect 
compared to linear one. This results suggest that cyclized Ir(III) have a higher potential of 
mitochondria-targeted PDT agents in cancer therapy. In case of green ir complexes, they don’t show 
photoinduced toxicity effect (Figure 2. 23).   
 
 
Figure 2. 23 Photodynamic therapy experiment for Green iridium complex . (a-b) Identification of 
two reactive oxygen species (superoxide radical and 1O2) generation with dihydrorhodamine 123 
(DHR 123) or 9, 10-anthracenediyl-bis(methylene)dimalonic acid (ABDA) before/after peptide 
binding. DHR 123 (left, bar graph) and ABDA assay (right, decay line) with Green. (c-f) Cellviability 
of Modified peptides with Green emitted iridium complex with(right) and without irradiation(left). 
Concentration: 10 μM. 100 mW cm−2 light; incubation time: 24h , irradiation time = 0(c), 60(d), 
300(e), 600s(f). (ABDA, DHR data taken by co-worker, Jung Seung Nam) 
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Figure 2. 23 Flow-cytometry analysis to measure the extend of apoptosis mediated cell death in linear 
& cyclic Red Ir complex conjugated peptides in HeLA cells after 8h incubation and irradiation with 
light (300s), analyzed by annexin-V-FITC (FL1-H) and propidium iodide (FL3-H) staining assay. 
10,000 events were counted to measure extend of apoptosis. Concentration: 20 μM.  
 
The cell death induced by the photo-excited cyclic and linear complexes was further investigated 
using annexin V/PI apoptosis assays. After treated HeLa cells with modified red one (10 μM) for 1h, 
sample exposed to irradiation for 5min then incubated for 12 h. As shown in Fig. 2.23, there was an 
increase in the percentages of cells in early apoptotic phase. While linear modified complexes showed 
similar percentage (69.1-69.6) of early apoptosis phase, cyclized complexes significantly rose to 84.2% 
(74.6-84.2) in early apoptosis part. The ability of this model cyclic complexes to induce apoptosis was 
more efficient their antitumor activity. 
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2.5 Conclusion 
 
In conclusion, we developed the simple, but, robust and efficient Photodynamic agents for cancer 
cells using cyclic corporation with selectivity in mitochondria. We design two type of iridium (III) 
complexes (Green and red emission region). Two complexes exhibited high level of photo physical 
properties. However, Green emitted iridium (III) complex shows only bioimaging ability. In contract, 
Red emitted iridium (III) complex shows non-invasive image with NIR region and photo-induced 
toxicity. By introducing cyclic MPPs to iridium (III) complexes, they enhance the selectivity to 
mitochondria, cellular uptake, and biocompatibility (soluble in water). Notably, cyclic form iridium 
(III) complexes were primarily localized in the mitochondria rather than liner form one. Finally, 
theses coordinated complexes generate ROS under irradiation, indeed, leading to apoptosis. 
Consequently, we think that this work is meaningful for designing and developing high effective 
organelle-targeted PDT agents, which has great potential in biomedical fields. 
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3. pH-resoponsive Mitochondria Penetrating Peptide with PU-H71 
derivatives for efficient anticancer therapy 
 
3.1 Abstract  
 
Stimuli responsive degradation of chemical bonds are useful tools for the development of ‘smart 
materials’ which have remarkable applications in stimuli responsive drug delivery system. The pH is 
commonly applied to the cancer specific drug delivery system, because the pH near the tumor or in 
the tumor extracellular environment significantly acidic as pH 6-6.5 while the normal physiological 
pH is around 7.4. In this study, we designed and developed mitochondria targeting short peptide with 
charge conversion depending on pH values. The peptide sequences consists of FxrFxKK, possess 
positive charge and lipophilic character for targeting mitochondria. We conjugated drug (PU-10-ester) 
as an inhibitor of HSP90 and Maleic derivatives which are play a role of hydrolyzed in MPPs. Once 
maleic conjugated MPP extravagates into cell membrane through highly permeability, amide bonds 
within conjugate occur hydrolysis, reproducing intrinsic properties of MPP in the acidic tumor 
extracellular fluids (pH < 7) for efficient cellular uptake and mitochondria targeting. Moreover, this 
platforms shows anticancer effect with 40% at 25 μM concentration. Therefore, we hope that this 
model conjugated peptides have a potent of cancer therapy agent. 
 
3.2 Introduction  
 
Stimuli responsive degradation of chemical bonds are useful tools for the development of ‘smart 
materials’ which have remarkable applications in stimuli responsive drug delivery system [1]. Among 
the various stimuli such as temperature, enzymes, pH etc., the pH is commonly applied to the cancer 
specific drug delivery system, because the pH near the tumor or in the tumor extracellular 
environment significantly acidic as pH 6-6.5 while the normal physiological pH is around 7.4 [2]. 
Moreover the pH of the endosome or lysosomes are even lower (pH 5.0-5.5) [3]. For example, Nano 
carriers that exhibit charge conversion with the pH-induced cleavage of the amide bond between an 
amin and 2,3-dimethylmaleic anhydride have been designed [4].  
 
 ４２ 
 
Cell-penetrating peptides (CPPs) including mitochondria penetrating peptides (MPPs) are highly 
cationic peptides usually rich in arginine and lysine amino acids, which have ability to relocate 
quickly into any live cells. Unfortunately, since they have their inherent non specificity caused by 
their cationic nature, many in vivo uses are limited. To suppress their nonspecific interaction, the 
cationic charges of CPPs are masked with poly anions [5]. For example, a CPP was conjugated with an 
anionic peptide via a cleavable linker in order to shield its nonspecific interactions. Once in the target 
tissues, hydrolysis of the linker used the disassociation of amide bonds, regenerating the CPP’s 
functions. 
 
The functional groups such as acetal, orthoester, imine, and phosphoramidate etc have ability to 
degrade under acidic pH (< 6.5) [6-9]. Recently, Maleic acid amide derivatives have been used as 
candidates of pH-sensitive moiety. They undergo cleavage in the acidic pH, due to the internal 
reaction of amide carbonyl group by the carboxylate, inducing change of chemical structure of maleic 
acid amide [10-11]. Upon the pH induced degradation, the negatively charged MA-MPP changes to 
positively charged MPP and hence facilitate the cellular uptake. This negative-to-positive charge 
conversion in maleic acid amide derivatives have been modified in order to increase the negative 
charge density of lipids and polymers for the effective pH-triggered drug delivery. By utilizing pH 
responsive system, pH-sensitive nanocarriers have been developed for tumor targeted drug delivery. 
Among them, Mitochondria penetrating peptides (MPPs) provide superior and potent properties; 1) 
almost MPPs contain lysine residues which can make β-carboxylic amides at neutral pH and quickly 
hydrolyze at acidic pH to reproduce the corresponding amines. 2) MPPs are CPPs, can enter both the 
plasma and mitochondrial membranes. So they can be ability to target mitochondria effectively. 3) 
MPPs can be easily to conjugate organic compound such as anticancer drugs and imaging dye with 
solubility in water (biocompatible). These strength of MPPs would enhance to selectively pH-
triggered drug delivery. 
 
In this study, we designed and developed mitochondria targeting short peptide with charge 
conversion depending on pH values. The peptide sequences consists of FxrFxKK, possess positive 
charge and lipophilic character for targeting mitochondria. We conjugated drug (PU-10-COOH) as an 
inhibitor of HSP90 and Maleic derivatives which are play a role of hydrolyzed in MPPs. Once maleic 
conjugated MPP extravagates into cell membrane through highly permeability, these amides are 
hydrolyzed, regenerating the pristine functioning MPP in the acidic tumor extracellular fluids (pH < 7) 
for fast cellular uptake and mitochondria targeting (Scheme 3.1). Moreover, this platforms shows 
anticancer effect with 40% at 25 μM concentration. Therefore, we hope that this model conjugated 
peptides have a potent of cancer therapy agent. 
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Scheme 3. 1 Schematic representation of charge conversion MPP 
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3 .3 Experimental  
 
 
3.3.1 Materials and Methods  
 
All reagents and chemicals were purchased from commercial sources and used as received. Amino 
acids (Fmoc-Lys(Boc)-OH, Fmoc-Phe-OH, Fmoc-d-arg(Boc)-OH, Fmoc-Cha-OH) and rink amide 
MBHA resin were obtained from BeadTech (Korea) and ApexBio (USA), Coupling reagent(O-
benzotriazole-N,N,N’,N’-tetramethyluronium hexafluorophosphate, HBTU) was obtained from 
ApexBio (USA). N,N-diisopropylethylamine(DIPEA) and trifluoroacetic acid (TFA) were purchased 
from TCI (Japan). Triisopropylsilane and piperidine were obtained from Sigma-Aldrich (USA). N,N-
dimethylformamide(DMF), Methanol and Acetonitrile (ACN) HPLC grade was purchased from 
DAEJUNG(South Korea).Dimethyl sulfoxide (DMSO) HPLC grade was from Fischer chemical 
(USA). Molecular sieves 4A, 4-8mesh and Magnesium sulfate (MgSO4) obtained from SAMCHUN 
CHEMICALS (South Korea). 4-Dimethylaminopyridine (DMAP) were purchased from GL Biochem 
Ltd (Shanghai, China), 12N Hydrochloric acid (HCl) was obtained from OCI Company Ltd (Korea). 
Methyl 10-hydroxydecanoate and Pyrene-butylic acid were obtained from Sigma-Aldrich (USA). 
Succinic anhydride, Maleic anhydride, Dimethyl maleic anhydride, Citraconic anhydride and Cis-
aconitic anhydride were obtained from Sigma-Aldrich (USA). Ethyl acetate (EtOAc) and DCM were 
obtained from SK Chemical (Korea). FxrFKK peptide, Pyrene-FxrFKK, FxrFKK-PUH71 and FxrFKK 
-10-PU prodrug were characterized using MALDI-TOF. PUH71 and PU-10-ether derivatives were 
characterized using 400MHz FT-NMR (Agilent Technologies).  
 
3.3.2 Synthesis of peptide (FxrFXKK) 
 
Solid phase peptide synthesis (SPPS) was performed by an automated peptide synthesizer. 200 mg of 
resin was swollen in DMF solution. After 30 min, operate machine to synthesize peptide. Peptide 
scale is 0.1mM. Amino acid solution was prepared by dissolving Fmoc-Lys(Boc)-OH 0.2821 g in 6 
mL DMF, Fmoc-d-arg(Boc)-OH 0.195 g in 3 mL DMF, And Fmoc-Cha-OH 0.117 g in 3 mL DMF. 
Fmoc deprotection of the Fmoc- amino acids was performed by adding 20% piperidine solution in 
DMF. HBTU and DIPEA act as coupling reagent and base. After finishing final deprotection of Fmoc 
protecting group, make cleavage cocktail (TFA: triisopropylsilane: Water = 4.75 mL : 0.25 mL: 0.25 
mL). Add cleavage cocktail into resin with stirring for 4 hours at room temperature. Then, precipitate 
with cold diethyl ether. The peptide is purified through HPLC using water/Acetonitrile. 
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3.3.3 Synthesis of pyrene-FxrFxKK 
 
Pyrene- FxrFXKK were obtain from manual synthesis. pyrene-butylic acid(200 mg,1eq), FxrFxKK 
peptide(200 mg,1 eq), DIPEA(300 μL,3 eq), and HBTU(298 mg,3 eq) in DMF 1 mL put in the 25 mL 
RBF and rotate for 24h. After 24h, deprotection of the Fmoc- amino acids was performed by adding 
20% piperidine solution in DMF. HBTU and DIEA act as coupling reagent and base. After finishing 
final deprotection of Fmoc protecting group, make cleavage cocktail (TFA: triisopropylsilane: Water = 
4.75 mL: 0.25 mL: 0.25 mL). Add cleavage cocktail into resin with stirring for 4 hours at room 
temperature. Then, precipitate with cold diethyl ether. The peptide is purified through HPLC using 
water/Acetonitrile. 
 
 
 
Scheme 3. 2 synthesis of Pyrene- FxrFKK 
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3.3.4 Synthesis of PUH71- COOH linker 
PUH71- COOH was obtain from reaction of between commercial available PHU71and succinic 
anhydride. PUH71(20 mg,1eq), succinic anhydride(3.9 mg,1eq) and DIPEA(50 mg,1 eq) in DMF 2 
mL put in the 25 mL RBF and rotate for 24 h. After 24 h, mixture is purified through HPLC using 
water/Methanol. 
 
3.3.5 Synthesis of PUH71- FxrFxKK 
PUH71- FxrFKK was obtain from reaction of between PHU71-COOH linker and peptide. PUH71(10 
mg,1 eq), FxrFKK peptide(100 mg,10 eq), DIPEA(300 μL,30 eq), and HBTU(298 mg, 30 eq) in DMF 
2 mL put in the 25 mL RBF and rotate for 24 h. After 24 h, deprotection of the Fmoc- amino acids 
was performed by adding 20% piperidine solution in DMF. HBTU and DIEA act as coupling reagent 
and base. After finishing final deprotection of Fmoc protecting group, make cleavage cocktail (TFA: 
triisopropylsilane: Water = 4.75 mL: 0.25 mL: 0.25 mL). Add cleavage cocktail into resin with stirring 
for 4 hours at room temperature. Then, precipitate with cold diethyl ether. The peptide is purified 
through HPLC using water/Methanol. 
 
3.3.6 Synthesis of PU- 10-COOH linker 
 
 
Scheme 3. 3 Overall schematic illustration of PU-10-COOH linker (Mitsunobu reaction[12]) 
 
 ４７ 
 
3.3.6 a) Synthesis 8-mercaptoadenine 
 
4,5,6-triamino pyrimidine, sodium bicarbonate and carbon disulfide were mixed in H2O and Ethanol 
(2:1) solution. And then mixture take a reaction for 72 h by using reflux. After finish the reaction, 
mixture evaporate to remove carbon disulfide then solid particle were obtain. CH3COOH 5 mL added 
this product and then filter some precipitate. δ_H (400 MHz, MeOH) 6.75 (2H, m) , 8.01 (1H, dt), 
7.54-7.63 (1H, m), 12.86-13.10 (1H, m). 
 
3.3.6 b) Synthesis 1-iodo-3,4-methylenedioxybenzene   
(methylenedioxy)aniline is dissolved in HCl(6.4 mL) and ice. A chilled solution of NaNO2 (6 mL 
water) was added over a time period of 15 min. then allowed to stir for an additional 10-15min. and 
sodium nitrile, urea and potassium added to mixture then stirred overnight. After finish the reaction, 
mixture was purified by extraction and column. Compound come on violet color but after evaporation, 
compound become dark brown. δ_H (400 MHz, CDCl3) 6.05 (2H, m), 6.54-6.63 (1H, m), 7.16 (2H, 
m). 
 
3.3.6 c) Synthesis of PU 
Mixture contained 8-mercaptoadenine, 1-iodo-3,4-methylenedioxybenzene, Neocuproin, CuI and 
Nao-tBu was dissolved in dry DMF and boild at 100~120℃ for 24h. 𝛿𝐻 (400 MHz, MeOH) 6.02-
6.23 (2H, m). 6.75-7.34 (1H, 1H, 1H, 1H, dt), 8.04-8.13 (1H, m), 12.86-13.10 (1H, m).  
 
3.3.6 d) Synthesis of PU-I 
Mixture contained PU, N-iodosuccinimide and TFA was dissolved in ACN and react for 24 h at 
room temp. After finish the reaction, mixture was purified by extraction and column. 𝛿𝐻 (400 MHz, 
MeOH) 6.02-6.23 (2H, m). 6.75-7.34 (1H, 1H, 1H, dt), 8.04-8.13 (1H, m), 12.86-13.10 (1H, m).  
 
3.3.6 e) Synthesis of PU-10- COOCH3 
Mixture contained PU-I, eyhyl-6-hydroxyhecanoate, tri-phenyl phosphine(PPH3) and Diethyl 
azodicarboxylate(DEAD) was dissolved in dry DCM and react for 24 h at room temp. After finish the 
reaction, mixture was purified by extraction and column. 𝛿𝐻 (400 MHz, MeOH) 1.32 (4H, m). 1.42-
1.58(6H, m). 1.64.1.74(3H, m). 1.80-1.95 (3H, m) 2.32 (3H, m). 4.01(3H, m). 4.04(4H, m). 6.02-6.23 
(2H, m). 6.75-7.34 (1H, 1H, 1H, dt), 8.04-8.13 (1H, m), 12.86-13.10 (1H, m).  
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3.3.6 f) Synthesis of PU-10- COOH 
Mixture contained PU-10-COOCH3 and KOH was dissolved in MeOH to remove methoxy unit and 
react at room temp for 24 h. After finish the reaction, mixture was purified by extraction and column. 
𝛿𝐻 (400 MHz, MeOH) 1.32 (4H, m). 1.42-1.58(6H, m). 1.64.1.74(3H, m). 1.80-1.95 (3H, m) 2.32 
(3H, m). 4.04(4H, m). 6.02-6.23 (2H, m). 6.75-7.34 (1H, 1H, 1H, dt), 8.04-8.13 (1H, m), 12.86-13.10 
(1H, m).  
 
3.3.7 Synthesis of PU-10- FxrFxKK 
PU-10-FxrFxKK was obtain from reaction of between PH-10-COOH linker and peptide. PU-10-
COOH(3 mg,1 eq), FxrFxKK peptide(30 mg,10 eq), DIPEA(30 μL,10eq), and HBTU(30 mg,10 eq) in 
DMF 1ml put in the 10ml RBF and rotate for 24h. After 24h, deprotection of the Fmoc- amino acids 
was performed by adding 20% piperidine solution in DMF. HBTU and DIEA act as coupling reagent 
and base. After finishing final deprotection of Fmoc protecting group, make cleavage cocktail (TFA: 
triisopropylsilane: Water = 4.75 mL: 0.25 mL: 0.25 mL). Add cleavage cocktail into resin with stirring 
for 4 h at room temperature. Then, precipitate with cold diethyl ether. The peptide is purified through 
HPLC using water/Methanol. 
 
3.3.8 Synthesis of Pyrene- FxrFKK –maleic derivatives 
Pyrene-FxrFxKK-maleic derivatives (Succinic anhydride, Maleic anhydride, Dimethyl maleic 
anhydride, Citraconic anhydride and Cis-aconitic anhydride) were obtain from manual synthesis. 
pyrene- FxrFKK peptide (1mg,1eq), DIPEA(3.5 μL,20 eq), and Maleic derivatives (2, 1.9, 2.5, 2.2, 3.1 
mg 20 eq seperatly) in DMF 1ml put in the 10ml RBF and rotate for 24 h. After 24 h, the peptide is 
through HPLC using water/Methanol. 
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3.3.9 Cell culture and cell viability analysis. 
Human cancer cells originating from cervix (HeLa) and noncancerous fibroblast (HeK293T) cells 
were obtained and cultured in DMEM, L-15 or RPMI (Life Technologies) containing 10% fetal 
bovine serum (FBS; Life Technologies) and 1% penicillin/streptomycin (Life Technologies) at 37ºC in 
a humidified atmosphere of 10% CO2. For cytotoxicity analysis, cells were cultured in sterile 96-well 
Nunc (Thermo Fisher Scientific Inc.) microtiter plate at a seeding density of 5 x 103 cells/well and 
allowed to settle for 24 h under incubation at 37 °C and 5% CO2 in their respective growth medium 
(RPMI 1640 and DMEM etc.). In order to check cell viability, the cells were then treated with 
different concentrations of peptides (0.01, 0.1, 0.5, 1, 2, 3, 5, 10, 15 and 20 µM). After 8h of 
incubation, stipulated time of light irradiation (3 min, 5 min and 10 min) was performed, Cell viability 
was measured at 24 h using the alamar blue assay, with each data point measured in triplicate. 
Fluorescence measurements were made using the plate reader (Tecan Infinite Series, Germany) by 
setting the excitation wavelength at 565 nm and monitoring emission at 590 nm on the 96 well plates. 
 
3.3.10 Confocal microscope imaging 
 HELA cells were seeded in one well glass cover glass (Lab Tek II, Thermo Scientific) at a seeding 
density of 2 x 105 cells/well. In order to check cellular uptake of peptides, the cells were then treated 
with different concentrations of peptides at 5 µM for 1h. The cellular uptake was monitored 
periodically using Olympus FV1000 microscope connected to CO2 incubator. 
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3.4 Results and Discussion  
 
1) Characteristic of Pyrene-MPP 
 
 
Figure 3. 1 MALDI-MS analysis of Pyrene-FxrFxKK. (M.W: 1006g/mol) 
 
 
We synthesized mitochondria penetrating peptide, which have a sequence of FxrFXKK (just call, 
MPP). To check the predominant mitochondria of peptide, we conjugated Pyene dye to peptide for 
imaging. As expected, our peptide can be accumulated in the mitochondria (Figure 3. 2) 
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Figure 3. 2 Pyrene with MPP peptide after 1h incubation in HeLA cells 
 
 
Next, we check the cell viability of conjugated peptide. Modified peptide shows almost non-toxic up 
to 50 μM with increasing concentration of peptide (Figure 3. 3). So, this peptide can be able to target 
organelle and possess biocompatibility. 
 
 
 
Figure 3. 3 Cell viability analysis for Pyrene-MPP peptides in HeLa cells under 24h incubation 
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2) Cell viability of Drug conjugated MPP (PUH71-MPP) 
 
Before using charge conversion properties, we firstly try to check the cell viability of drug-MPP. We 
want to know how much affect to anticancer ability without charge conversion units. So, we 
conjugated drug to peptide. PU-H71 is kind of HSP90 inhibitor and it can be used as an anti-cancer 
drug. HSP90 can be degraded and suppress the growth of tumor cell. So it is important that block the 
effect of HSP90 in the cell to treat the cancer. To attach PUH71 into peptide, PUH71was tethered 
succinic anhydride. Succinic anhydride can be make the carboxylic acid group, which can react with –
NH2 in peptide. We make drug-MPP and then confirm cell viability. PUH71-MPP shows toxicity but 
that much high compared to free drug. We thought about that and we came up with some idea. Since 
drug is highly closed to peptide residues, drug could be inhibited with turbidity. So, we made new 
drug with longer linker than previous one in order to reduce turbidity. 
 
 
Figure 3. 4 1H-NMR spectra of PUH71-COOH linker (400MHz, MeOH).  
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Figure 3. 5 MALDI-MS analysis of PUH71-FxrFxKK. (M.W: 1,330 g/mol) 
 
 
Figure 3. 6 Cell viability analysis for PuH71-MPP peptide and PuH71 drug in HeLa cells after 48h 
incubation using the Alamar blue dye assay. 
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3) Characterization data of PU-10-linker 
  
 
Figure 3. 7 1H-NMR spectra of 8-mercaptoadenine (400MHz, MeOH).  
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Figure 3. 8 1H-NMR spectra of 1-iodo-3,4-methylenedioxybenzene (400MHz, CDCl3).  
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Figure 3. 9 1H-NMR spectra of PU (400MHz, MeOH).  
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Figure 3. 10 1H-NMR spectra of PU-I (400MHz, MeOH).  
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Figure 3. 11 1H-NMR spectra of PU-10-COOCH3 (400MHz, MeOH).  
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Figure 3. 12 1H-NMR spectra of PU-10-COOH (400MHz, MeOH).  
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Figure 3. 13 MALDI-MS analysis of PU-10- FxrFxKK 
 
 
 
Figure 3. 14 Cell viability analysis for Pu-10-MPP peptide (a) in HeLa cells after 24h incubation. (b) 
Compared cell viability of PU-H71,PU-H71-MPP and PU-10-MPP at concentration 2, 20 μM. 
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4) Hydrolysis of pyrene-MPP-Maleic derivatives 
 
 
Figure 3. 15 MALDI-MS analysis of Pyene-FxrFxKK- succinic anhydride 
 
To utilize charge conversion, we attached maleic derivatives to MPP. Firstly, we try to conjugate 
succinic anhydride to MPP. We get the succinic-MPP(Figure 3.10). But succinic anhydride group 
don’t show degradation at the mild acidic condition (No data). So, we try to attach maleic derivatives 
with MPP. Among the maleic group, citraconic anhydride and aconitic anhydride are well kwon as 
degradation at acidic condition. Based on this knowledge, we synthesize the citraconic-MPP (Figure 
3.11). and then we check the degradation of citraconic-MPP. After 1h rotation time at pH 5.5, 
Citraconic group occur the hydrolysis, which means it also can be used for charge conversion 
system(Figure 3.15).     
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Figure 3. 16 MALDI-MS analysis of Pyene-FxrFxKK- citraconic anhydride 
 
Figure 3. 17 HPLC analysis of MPP-citraconic conjugate depending on reaction time at acidic pH 5.5.  
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3.5 Conclusion and future work 
 
In this research, we synthesize mitochondrial targeting charge conversion of peptide depending on 
pH. The peptide sequences consists of FxrFxKK, just called MPP, possess positive charge and 
lipophilic character for targeting mitochondria. Primary amines of lysine and arginine residues are the 
main cause of the nonspecific interactions, but they also play a key role in their membrane 
transduction   
 
PU-H71 is kind of HSP90 inhibitor and it can be used as an anti-cancer drug. HSP90 can be 
degraded and suppress the growth of tumor cell. So it is important that block the effect of HSP90 in 
the cell to treat the cancer. To attach PUH71 into peptide, PUH71was tethered succinic anhydride. 
Succinic anhydride can be make the carboxylic acid group, which can react with –NH2 in peptide. We 
make drug-MPP and then confirm cell viability. PUH71-MPP shows toxicity but that much high 
compared to free drug. We thought about that and we came up with some idea. Since drug is highly 
closed to peptide residues, drug could be inhibited with turbidity. So, we made new drug with longer 
linker than previous one in order to reduce turbidity. And we conjugated new synthesized drug (PU-
10-COOH) as an inhibitor of HSP90. This platforms shows anticancer effect with 55~58% at 20 μM 
concentration. So, we hope that this model conjugated peptides have a potent of cancer therapy agent. 
  
Finally, some β-carboxylic amides are stable at neutral pH but quickly hydrolyze at acidic pH to 
regenerate the corresponding amines. Most of maleic derivatives can be able to degrade at mild acidic 
pH conditions since these moieties can be attributed to the internal attack of amide carbonyl group by 
the carboxylate, inducing change of the chemical structure of maleic acid amide. Maleic derivatives 
which are play a role of hydrolyzed in MPPs. Once maleic conjugated MPP extravagates into cell 
membrane through highly permeability, these amides are hydrolyzed, regenerating the pristine 
functioning MPP in the acidic tumor extracellular fluids (pH < 7) for fast cellular uptake and 
mitochondria targeting. So our designed peptide also could be more potent to selective ability for 
targeted organelles. Through this result, we planned detail experiments to get more clear evidence by 
adjusting maleic derivatives to MPP. Further investigation with drug and targeting efficiency will be 
examined.  
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